Core Viewpoint - Jimin Health (603222) announced that its subsidiary, Hainan Jimin Boao International Hospital Co., Ltd., received the acceptance notice for the clinical trial application of DB006 on September 26, 2025, from the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Company Summary - The DB006 oncolytic adenovirus injection is a gene therapy drug aimed at treating advanced malignant solid tumors [1]